Надикса 1% крем - 25g বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

Надикса 1% крем - 25g

ferrer international s.a. -

Zineryt 40 mg/ml +12 mg/ml powder and solvent for cuteanopus solution বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

zineryt 40 mg/ml +12 mg/ml powder and solvent for cuteanopus solution

astellas pharma d.o.o. - Еритромицин, комбинации - 40 mg/ml +12 mg/ml powder and solvent for cuteanopus solution

Dalacin T 10 mg/ml cutaneous solution  বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

dalacin t 10 mg/ml cutaneous solution 

pfizer enterprises sarl - Клиндамицин - 10 mg/ml cutaneous solution 

Duac  10 mg/g + 30 mg/g gel বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

duac  10 mg/g + 30 mg/g gel

ГлаксоСмитКлайн ЕООД - 10 mg/g + 30 mg/g gel

Erythran 1% ointment বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

erythran 1% ointment

Актавис ЕАД - Еритромицин - 1% ointment

Davercin 25 mg/g gel বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

davercin 25 mg/g gel

tarchomin pharmaceutical works polfa" s.a." - Еритромицин - 25 mg/g gel

Acnex  10 mg/g + 0,25 mg/g gel বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

acnex  10 mg/g + 0,25 mg/g gel

meda pharma gmbh & co. kg - 10 mg/g + 0,25 mg/g gel

Acnerin, sol.cut.3% - 100ml বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

acnerin, sol.cut.3% - 100ml

Унифарм - АД - Еритромицин -

Tafinlar ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

tafinlar

novartis europharm limited - dabrafenib mesilate - Меланомът - Антинеопластични средства - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 и 5. Помощните терапия melanomadabrafenib в комбинация с trametinib е показан за адъювантного лечение на възрастни пациенти с iii състояние на меланом с Браф v600 мутация далеч, след пълна резекция на. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.

Braftovi ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

braftovi

pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - Антинеопластични средства - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.